TipRanks
Go Ultimate55% OFF

Charles Faith L. Insider Profile

4 Followers

Charles Faith L. , Director at CNS Pharmaceuticals, holds 7.10K shares in CNS Pharmaceuticals (Ticker: CNSP), holds 176.41K shares in Abeona Therapeutics (Ticker: ABEO), holds ― shares in Avenue Therapeutics (Ticker: ATXI). Most recently, Charles Faith L. Bought ― shares of CNS Pharmaceuticals on May 20, 2026 for an estimated value of $33.94K.

Charles Faith L. 's Trading History

CNSP
CNS Pharmaceuticals
May 20, 2026DirectorInformative Buy33.94K$35.50K
ABEO
Abeona Therapeutics
Jan 27, 2026DirectorUninformative Buy―$767.37K
CDT
CDT Equity
Apr 17, 2025DirectorUninformative Buy99.07K$11.24K
ATXI
Avenue Therapeutics
―Director――

You May Also Like

Charles Faith L. insider profile FAQ

What is the percentage of profitable transactions made by Charles Faith L. ?
The percentage of profitable transactions made by Charles Faith L. is 50%.
What is the average return per transaction made by Charles Faith L. ?
The average return per transaction made by Charles Faith L. is 12.70%.
What stocks does Charles Faith L. hold?
Charles Faith L. holds: CNSP, ABEO, ATXI, CDT stocks.
What was Charles Faith L. ’s latest transaction?
Charles Faith L. ’s latest transaction was an Informative Buy of $33.94K.
What was Charles Faith L. 's most profitable transaction?
Charles Faith L. ’s most profitable transaction was an Informative Buy of ABEO stock on April 29, 2024. The return on the trade was 54.00%.
What is Charles Faith L. 's role in CNS Pharmaceuticals?
Charles Faith L. 's role in CNS Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.